Nanoparticle Albumin Bound Paclitaxel in the Treatment of Human Cancer: Nanodelivery Reaches Prime-Time?. (2nd May 2013)

• Record Type: Journal Article
• Authors: Cucinotto, Iole; Fiorillo, Lucia; Gualtieri, Simona; Arbitrio, Mariamena; Ciliberto, Domenico; Staropoli, Nicoletta; Grimaldi, Anna; Luce, Amalia; Tassone, Pierfrancesco; Caraglia, Michele; Tagliaferri, Pierosandro
• Other Names: De Rosa Giuseppe Academic Editor.
• Is Part Of: Journal of drug delivery. Volume 2013(2013)
• Publication Date: 2013-05-02
• Subjects: Drug delivery systems -- Periodicals; 615.605
• DOI: 10.1155/2013/905091
• Languages: English
• ISSNs: 2090-3014

Abstract

Abstract : Nanoparticle albumin bound paclitaxel (nab-paclitaxel) represents the first nanotechnology-based drug in cancer treatment. We discuss the development of this innovative compound and report the recent changing-practice results in breast and pancreatic cancer. A ground-breaking finding is the demonstration that nab-paclitaxel can not only enhance the activity and reduce the toxicity of chromophore-diluted compound, but also exert activity in diseases considered refractory to taxane-based treatment. This is the first clinical demonstration of major activity of nanotechnologically modified drugs in the treatment of human neoplasms.